ZYDUSLIFE

Zydus Lifesciences Share PriceZydus Lifesciences

₹479.45
9.3 (1.98%)
  • Advice
  • Hold
As on 07 February, 2023 | 16:46 BSE: 532321 NSE: ZYDUSLIFE

Zydus Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Zydus Lifesciences

Start SIP

Zydus Lifesciences Share Price

  • Over 1 Month 11.32%
  • Over 3 Month 8.94%
  • Over 6 Month 34.07%
  • Over 1 Year 17.15%

Zydus Lifesciences Key Statistics

P/E Ratio 23.5
PEG Ratio -0.4
Market Cap Cr 48,530
Price to Book Ratio 2.5
EPS 10.8
Dividend 0.5
Relative Strength Index 69.9
Money Flow Index 67.2
MACD Signal 3.68
Average True Range 13.01

Zydus Lifesciences Investment Rating

  • Master Rating:
  • Zydus Lifesciences has an operating revenue of Rs. 16,433.50 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 19% is great, ROE of 26% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 21% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Zydus Lifesciences Financials
IndicatorDec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,0872,2171,9811,919
Operating Expenses Qtr Cr 1,6281,7201,4371,562
Operating Profit Qtr Cr 459679544458
Depreciation Qtr Cr 122124123123
Interest Qtr Cr 89644142
Tax Qtr Cr 129149101100
Net Profit Qtr Cr 256451332247

Zydus Lifesciences Technicals

EMA & SMA

Current Price
₹479.45
9.3 (1.98%)
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 437.03
  • 50 Day
  • 428.15
  • 100 Day
  • 416.39
  • 200 Day
  • 409.89
  • 20 Day
  • 440.41
  • 50 Day
  • 424.97
  • 100 Day
  • 415.44
  • 200 Day
  • 387.96

Zydus Lifesciences Resistance and Support

PIVOT
₹464.54
Resistance
First Resistance 482.12
Second Resistance 494.09
Third Resistance 511.67
RSI 69.91
MFI 67.2
MACD Single Line 3.68
MACD 4.66
Support
First Resistance 452.57
Second Resistance 434.99
Third Resistance 423.02

Zydus Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,650,400 42,860,888 25.97
Week 1,052,458 36,709,742 34.88
1 Month 1,200,092 52,444,027 43.7
6 Month 1,352,271 55,483,669 41.03

Zydus Lifesciences Result Highlights

Zydus Lifesciences Synopsis

NSE-Medical-Generic Drugs

Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 7981.90 Cr. and Equity Capital is Rs. 102.40 Cr. for the Year ended 31/03/2022. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
Market Cap 48,485
Sales 8,486
Shares in Float 25.31
No of funds 218
Yield 0.53
Book Value 3.64
U/D Vol ratio 1.8
LTDebt / Equity 1
Alpha 0.08
Beta 0.81

Zydus Lifesciences

Owner NameDec-22Sep-22Jun-22Mar-22
Promoters 74.98%74.98%74.88%
Mutual Funds 5.56%5.36%4.62%
Insurance Companies 7.87%7.3%7.3%
Foreign Portfolio Investors 2.52%2.61%2.86%
Financial Institutions/ Banks 0.01%
Individual Investors 7.04%7.6%8.02%
Others 2.03%2.14%2.32%

Zydus Lifesciences Management

Name Designation
Mr. Pankaj R Patel Chairman
Dr. Sharvil P Patel Managing Director
Mr. Ganesh N Nayak Executive Director
Mr. Bhadresh K Shah Independent Director
Mr. Mukesh M Patel Non Executive Director
Mr. Nitin R Desai Independent Director
Ms. Dharmishtaben N Raval Independent Woman Director
Ms. Apurva S Diwanji Independent Director

Zydus Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Zydus Lifesciences Corporate Action

Date Purpose Remarks
2023-02-03 Quarterly Results
2022-11-11 Quarterly Results
2022-08-10 Quarterly Results
2022-05-20 Audited Results, Dividend & Buy Back
2022-02-03 Quarterly Results
Date Purpose Remarks
2022-07-29 FINAL Rs.2.50 per share(250%)Final Dividend

Zydus Lifesciences MF Shareholding

Name Amount(cr)
Kotak Flexicap Fund Growth 37418
ICICI Prudential Bluechip Fund Growth 35049
Parag Parikh Flexi Cap Regular Growth 28248
Kotak Emerging Equity Scheme Growth 23335
Kotak Equity Arbitrage Fund Growth 21566

About Company

Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories. 

The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide. 

The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.

Business Verticals

Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.  

In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.

 

Milestones

1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.

1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.

2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.

2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.

2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.

2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd

2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.

2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.

2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.

2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.

2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.
 

Zydus Lifesciences FAQs

What is Share Price of Zydus Lifesciences ?

Zydus Lifesciences share price is ₹479 As on 07 February, 2023 | 16:32

What is the Market Cap of Zydus Lifesciences ?

The Market Cap of Zydus Lifesciences is ₹48530.1 Cr As on 07 February, 2023 | 16:32

What is the P/E ratio of Zydus Lifesciences ?

The P/E ratio of Zydus Lifesciences is 23.5 As on 07 February, 2023 | 16:32

What is the PB ratio of Zydus Lifesciences ?

The PB ratio of Zydus Lifesciences is 2.5 As on 07 February, 2023 | 16:32

What were the company's most recent reported sales and net income?

Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20  crores in FY22

What is the future of the company's shares?

Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.

How to buy shares of Zydus Lifesciences Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23